# Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT07432087** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Yue He, MD** · enrollment: 246 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Camrelizumab and Cetuximab
- **DRUG:** Camrelizumab and Chemotherapy

## Key facts

- **NCT ID:** NCT07432087
- **Lead sponsor:** Yue He, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2030-12-31
- **Final completion:** 2033-12-31
- **Target enrollment:** 246 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07432087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07432087, "Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07432087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*